1-20 of 24
Kian-Huat Lim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT130: Epacadostat with preoperative chemoradiation in locally advanced rectal cancer (LARC): Results of a translational phase I clinical trial

Haeseong Park, Katrina Pedersen, Katherine Huang, Matthew Mutch, Hyun Kim, Nikolaos Trikalinos, Olivia Aranha, Benjamin Tan, Rama Suresh, Lee Ratner, Moh'd Khushman, John Visconti, Kian-Huat Lim, Lauren Henke, Maddie Swiecicki, Jingxia Liu, Parag Parikh, Matthew Ciorba
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT130.
https://doi.org/10.1158/1538-7445.AM2024-CT130
Published: 05 April 2024
View article titled, Abstract CT130: Epacadostat with preoperative chemoradiation in locally advanced rectal cancer (LARC): Results of a translational phase I clinical trial
Journal Articles

Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal, Yuefan Wang, Andrew T. Shinkle, Michael C. Wendl, Tina M. Primeau, Yanyan Zhao, Alanna Gould, Hua Sun, Jacqueline L. Mudd, Jeremy Hoog, R. Jay Mashl, Matthew A. Wyczalkowski, Chia-Kuei Mo, Ruiyang Liu, John M. Herndon, Sherri R. Davies, Di Liu, Xi Ding, Yvonne A. Evrard, Bryan E. Welm, David Lum, Mei Yee Koh, Alana L. Welm, Jeffrey H. Chuang, Jeffrey A. Moscow, Funda Meric-Bernstam, Ramaswamy Govindan, Shunqiang Li, James Hsieh, Ryan C. Fields, Kian-Huat Lim, Cynthia X. Ma, Hui Zhang, Li Ding, Feng Chen
Journal: Cancer Research
Cancer Res (2023) 83 (24): 4161–4178.
https://doi.org/10.1158/0008-5472.CAN-23-0604
Published: 15 December 2023
View article titled, Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
Open the PDF for Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract 2620: TRIM4 is the E3 ubiquitin-ligase for TPL2/MAP3K8 and is modulated by oncogenic KRAS

Sapana Prakashrao Bansod, Paarth B. Dodhiawala, Ashenafi Bulle, Peng Liu, Lin Li, Patrick M. Grierson, Jason Held, Kian-Huat Lim
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2620.
https://doi.org/10.1158/1538-7445.AM2023-2620
Published: 04 April 2023
View article titled, Abstract 2620: TRIM4 is the E3 ubiquitin-ligase for TPL2/MAP3K8 and is modulated by oncogenic KRAS
Journal Articles

Abstract 3870: TNF-MK2 signaling drives protective autophagy following MAPK pathway inhibition in pancreatic cancer

Iftikhar Ali Khawar, Qing Wei, Timothy Hung-Po Chen, Lin Lin, Patrick M. Grierson, Kian-Huat Lim
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3870.
https://doi.org/10.1158/1538-7445.AM2023-3870
Published: 04 April 2023
View article titled, Abstract 3870: TNF-MK2 signaling drives protective autophagy following MAPK pathway inhibition in pancreatic cancer
Journal Articles

Abstract PO-003: CRESTONE – Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) Fusions – A phase 2 study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210)

Johanna C. Bendell, Kian-Huat Lim, Mark E. Burkard, Jessica J. Lin, Young Kwang Chae, Mark A. Socinski, Gazala Khan, Karen L. Reckamp, Shawn Leland, Douglas Plessinger, Lori Kunkel, Efrat Dotan, Gregory Otterson, Sai-Hong Ignatius Ou, Tejas Patil, John V. Heymach, Edward S. Kim
Journal: Cancer Research
Cancer Res (2020) 80 (22_Supplement): PO-003.
https://doi.org/10.1158/1538-7445.PANCA20-PO-003
Published: 13 November 2020
View article titled, Abstract PO-003: CRESTONE – Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) Fusions – A phase 2 study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210)
Journal Articles

Abstract PO-017: Targeting NF-kB pathway through IRAK4 renders immune checkpoint blockade effective in pancreatic cancer

Daoxiang Zhang, Vikas Somani, Paarth B. Dodhiawala, Patrick M. Grierson, Lin Li, Kuljeet Seehra, Xiuting Liu, Brett L. Knolhoff, Marianna B. Ruzinova, David G. DeNardo, Kian-Huat Lim
Journal: Cancer Research
Cancer Res (2020) 80 (22_Supplement): PO-017.
https://doi.org/10.1158/1538-7445.PANCA20-PO-017
Published: 13 November 2020
View article titled, Abstract PO-017: Targeting NF-kB pathway through IRAK4 renders immune checkpoint blockade effective in pancreatic cancer
Journal Articles

Abstract 3039: Essential role of IRAK4/TPL2 signaling axis in MAPK activation by oncogenic RAS and genotoxic stress

Paarth B. Dodhiawala, Namrata Khurana, Daoxiang Zhang, Yi Cheng, Lin Li, Kuljeet Seehra, Hongmei Jiang, Patrick M. Grierson, Andrea Wang-Gillam, Marianna B. Ruzinova, Kian-Huat Lim
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 3039.
https://doi.org/10.1158/1538-7445.AM2020-3039
Published: 15 August 2020
View article titled, Abstract 3039: Essential role of IRAK4/TPL2 signaling axis in MAPK activation by oncogenic RAS and genotoxic stress
Journal Articles

Abstract CT118: Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer: Experiences of pancreatic ductal adenocarcinoma (PDAC) patients

Andrea Wang-Gillam, Robert McWilliams, A. Craig Lockhart, Benjamin R Tan, Rama Suresh, Kian-Huat Lim, Katrina S. Pedersen, Nikolaos Trikalinos, Olivia Aranha, Haeseong Park, Lee Ratner, Nicholas Boice, David G. Denardo
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT118.
https://doi.org/10.1158/1538-7445.AM2020-CT118
Published: 15 August 2020
View article titled, Abstract CT118: Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer: Experiences of pancreatic ductal adenocarcinoma (PDAC) patients
Journal Articles

Abstract CT135: A phase 1b study of palbociclib + nab-paclitaxel in patients (pts) with metastatic adenocarcinoma of the pancreas (PDAC)

Manuel Hidalgo, Rocio Garcia Carbonero, Kian-Huat Lim, Wells Messersmith, Ignacio Garrido-Laguna, Erkut Borazanci, Andrew Lowy, Laura Medina Rodriguez, Daniel Laheru, Xin Huang, Meggan Tammaro, Jean-François Martini, Arthur Kudla, Kenneth Kern, Teresa Macarulla
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT135.
https://doi.org/10.1158/1538-7445.AM2020-CT135
Published: 15 August 2020
View article titled, Abstract CT135: A phase 1b study of palbociclib + nab-paclitaxel in patients (pts) with metastatic adenocarcinoma of the pancreas (PDAC)
Journal Articles

Abstract CT234: Phase I study of epacadostat added to preoperative chemoradiation in patients with locally advanced rectal cancer

Haeseong Park, Ebunoluwa Otegbeye, Hyun Kim, Matthew Mutch, Katrina Pedersen, Manik Amin, Benjamin Tan, Nikolaos Trikalinos, Kian-Huat Lim, Olivia Aranha, Rama Suresh, Shahed Badiyan, Matthew Silviera, Lauren Henke, Paul Wise, Steven Hunt, Jonathan Mitchem, Esther Lu, Andrea Wang-Gillam, Matthew Ciorba
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT234.
https://doi.org/10.1158/1538-7445.AM2020-CT234
Published: 15 August 2020
View article titled, Abstract CT234: Phase I study of epacadostat added to preoperative chemoradiation in patients with locally advanced rectal cancer
Journal Articles

Abstract 1941: Constitutive IRAK4 activation contributes to NF-κB activity and chemoresistance in colorectal cancer

Qiong Li, Lin Li, Daoxiang Zhang, Hongmei Jiang, Andrea Wang-Gillam, Marianna B. Ruzinova, Kian-Huat Lim
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1941.
https://doi.org/10.1158/1538-7445.AM2018-1941
Published: 01 July 2018
View article titled, Abstract 1941: Constitutive IRAK4 activation contributes to NF-κB activity and chemoresistance in colorectal cancer
Journal Articles

Abstract 2375: Concurrent HER or PI3K inhibition potentiates the anti-tumor effect of ERK inhibitor BVD-523 (ulixertinib) in preclinical pancreatic cancer models

Hongmei Jiang, Mai Xu, Lin Li, Maureen Highkin, Daoxiang Zhang, Qiong Li, Andrea Wang-Gillam, Kian-Huat Lim
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2375.
https://doi.org/10.1158/1538-7445.AM2018-2375
Published: 01 July 2018
View article titled, Abstract 2375: Concurrent HER or PI3K inhibition potentiates the anti-tumor effect of ERK inhibitor BVD-523 (ulixertinib) in preclinical pancreatic cancer models
Journal Articles

Abstract 995: Tumor-stroma IL-1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemo-resistance and is associated with poor prognosis in pancreatic cancer

Daoxiang Zhang, Lin Li, Hongmei Jiang, Andrea Wang-Gillam, Jinsheng Yu, Richard Head, Jingxia Liu, Marianna B Ruzinova, Kian-Huat Lim
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 995.
https://doi.org/10.1158/1538-7445.AM2018-995
Published: 01 July 2018
View article titled, Abstract 995: Tumor-stroma IL-1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemo-resistance and is associated with poor prognosis in pancreatic cancer
Journal Articles

Tumor–Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer

Daoxiang Zhang, Lin Li, Hongmei Jiang, Qiong Li, Andrea Wang-Gillam, Jinsheng Yu, Richard Head, Jingxia Liu, Marianna B. Ruzinova, Kian-Huat Lim
Journal: Cancer Research
Cancer Res (2018) 78 (7): 1700–1712.
https://doi.org/10.1158/0008-5472.CAN-17-1366
Published: 01 April 2018
View article titled, Tumor–Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer
Open the PDF for Tumor–Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 181: Constitutive IRAK1/4 kinase activation contributes to NF-kB activity and chemoresistance in pancreatic cancer

Daoxiang Zhang, Lin Li, Hongmei Jiang, Jinsheng Yu, Brett Knolhoff, Richard Head, Albert C. Lockhart, David G. DeNardo, Andrea Wang-Gillam, Marianna B. Ruzinova, Kian-Huat Lim
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 181.
https://doi.org/10.1158/1538-7445.AM2016-181
Published: 15 July 2016
View article titled, Abstract 181: Constitutive IRAK1/4 kinase activation contributes to NF-kB activity and chemoresistance in pancreatic cancer
Journal Articles

Abstract 2040: Mutations in SF3B1 lead to aberrant splicing through cryptic 3′ splice site selection and impair hematopoietic cell differentiation

Silvia Buonamici, Samantha Perino, Kian Huat Lim, Jacob Feala, Rachel Darman, Esther Obeng, Richard R. Furman, Suzanna Bailey, Gregg Keaney, Pavan Kumar, Yoshiharu Mizui, Eunice Park, John Wang, Markus Warmuth, Lihua Yu, Ping Zhu, Benjamin L. Ebert, Peter Smith
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 2040.
https://doi.org/10.1158/1538-7445.AM2015-2040
Published: 01 August 2015
View article titled, Abstract 2040: Mutations in SF3B1 lead to aberrant splicing through cryptic 3′ splice site selection and impair hematopoietic cell differentiation
Journal Articles

Abstract 2932: SF3B1 mutations induce aberrant mRNA splicing in cancer and confer sensitivity to spliceosome inhibition

Silvia Buonamici, Kian Huat Lim, Jacob Feala, Eunice Park, Laura Corson, Michelle Aicher, Daniel Aird, Betty Chan, Erik Corcoran, Rachel Darman, Peter Fekkes, Gregg Keaney, Pavan Kumar, Kaiko Kunii, Linda Lee, Xiaoling Puyang, Jose Rodrigues, Anand Selvaraj, Michael Thomas, John Wang, Markus Warmuth, Lihua Yu, Ping Zhu, Peter Smith, Yoshiharu Mizui
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2932.
https://doi.org/10.1158/1538-7445.AM2014-2932
Published: 01 October 2014
View article titled, Abstract 2932: SF3B1 mutations induce aberrant mRNA splicing in cancer and confer sensitivity to spliceosome inhibition
Journal Articles

Abstract 2332: Oncogenic MYD88 mutants require Toll-like receptors.

Kian-Huat Lim, Gregory M. Barton, Louis M. Staudt
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 2332.
https://doi.org/10.1158/1538-7445.AM2013-2332
Published: 15 April 2013
View article titled, Abstract 2332: Oncogenic <em>MYD88</em> mutants require Toll-like receptors.
Journal Articles

Abstract 4543: High-throughput combination screening identifies novel drug-drug pairings for a Bruton's tyrosine kinase inhibitor against the ABC subtype of diffuse large B-cell lymphomas.

Lesley A. Mathews, Rajarshi Guha, Paul Shinn, Ryan M. Young, Kian-Huat Lim, Jonathan Keller, Dongbo Liu, Adam Yasgar, Crystal McKnight, Matthew B. Boxer, Damien Y. Duveau, Jian-kang Jiang, Sam Michael, Bryan T. Mott, Paresma R. Patel, William Leister, David J. Maloney, Christopher A. LeClair, Ganesha Rai, Ajit Jadhav, Brian D. Peyser, Christopher P. Austin, Scott Martin, Anton Simeonov, Marc Ferrer, Louis Staudt, Craig J. Thomas
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 4543.
https://doi.org/10.1158/1538-7445.AM2013-4543
Published: 15 April 2013
View article titled, Abstract 4543: High-throughput combination screening identifies novel drug-drug pairings for a Bruton's tyrosine kinase inhibitor against the ABC subtype of diffuse large B-cell lymphomas.
Journal Articles

The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis

Yi-Shan Lee, Kian-Huat Lim, Xing Guo, Yoshiharu Kawaguchi, Yasheng Gao, Tomasa Barrientos, Peter Ordentlich, Xiao-Fan Wang, Christopher M. Counter, Tso-Pang Yao
Journal: Cancer Research
Cancer Res (2008) 68 (18): 7561–7569.
https://doi.org/10.1158/0008-5472.CAN-08-0188
Published: 14 September 2008
View article titled, The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis
Open the PDF for The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis in another window
Includes: Supplementary data